Results from Phase 1/2 Study of Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-™T) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to Standard Therapies,

1 week ago 3

1. Homepage
2. Finance
3. Results from Phase 1/2 Study of Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-™T) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to Standard Therapies,